Evidence map›Paper›PMID 39408276›Full record

ArticleNutrients2024

Oral Trehalose Intake Modulates the Microbiota-Gut-Brain Axis and Is Neuroprotective in a Synucleinopathy Mouse Model.

Solène Pradeloux, Katherine Coulombe, Alexandre Jules Kennang Ouamba, Amandine Isenbrandt, Frédéric Calon, Denis Roy, Denis Soulet

Abstract read
In one paragraph

Article in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trehalose's untapped mechanisms in alzheimer's: gut-brain-autophagy signalling beyond the usual targets.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. The role of amphipathic and cationic helical peptides in Parkinson's disease.Protein science : a publication of the Protein Society · 2025
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Solène PradelouxCentre de Recherche du CHU de Québec, Québec, QC G1V 4G2, Canada.ORCID 0009-0004-0073-5338
Katherine CoulombeCentre de Recherche du CHU de Québec, Québec, QC G1V 4G2, Canada.
Alexandre Jules Kennang OuambaCentre de Recherche du CHU de Québec, Québec, QC G1V 4G2, Canada.ORCID 0000-0003-4050-9787
Amandine IsenbrandtCentre de Recherche du CHU de Québec, Québec, QC G1V 4G2, Canada.
Frédéric CalonCentre de Recherche du CHU de Québec, Québec, QC G1V 4G2, Canada.ORCID 0000-0002-4203-0887
Denis RoyCentre de Recherche du CHU de Québec, Québec, QC G1V 4G2, Canada.ORCID 0000-0002-4229-9245
Denis SouletCentre de Recherche du CHU de Québec, Québec, QC G1V 4G2, Canada.ORCID 0000-0002-0937-7061

Funding

Canadian Funds for InnovationCIHR 202209PJ8-491134Desjardins Training Grant for Research and Innovation from the Fondation du CHU de QuébecFaculty funds from Université Laval (Trifaculty initiative)Fellowship from the Faculty of Pharmacy Teaching and Research Fund (FER), Laval UniversityJunior 2 career award from Fonds de Recherche du Québec - Volet SantéSentinelle Nord Funds (Excellence Canada)
6 · The paper itself

Abstract

Parkinson's disease (PD) is a neurodegenerative disease affecting dopaminergic neurons in the nigrostriatal and gastrointestinal tracts, causing both motor and non-motor symptoms. This study examined the neuroprotective effects of trehalose. This sugar is confined in the gut due to the absence of transporters, so we hypothesized that trehalose might exert neuroprotective effects on PD through its action on the gut microbiota. We used a transgenic mouse model of PD (PrP-A53T G2-3) overexpressing human α-synuclein and developing GI dysfunctions. Mice were given water with trehalose, maltose, or sucrose (2%

Indexed as

Brain-Gut AxisDisease Models, AnimalGastrointestinal MicrobiomeMice, TransgenicNeuroprotective AgentsTrehaloseAdministration, Oralalpha-SynucleinAnimalsGlucagon-Like Peptide 1HumansMaleMaltoseMiceParkinson DiseaseSynucleinopathiesalpha-SynucleinGlucagon-Like Peptide 1MaltoseNeuroprotective AgentsTrehaloseGLP-1gut microbiotamicrobiota–gut–brain axisParkinson’s diseasePrP-A53Ttrehalose

Identifiers

PMID39408276
PMCPMC11478413

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.